ARGX-109 for Healthy Subjects
Trial Summary
Do I need to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
How is the drug ARGX-109 different from other treatments?
ARGX-109, which involves the use of L-arginine, is unique because it focuses on improving metabolic profiles by enhancing lean tissue deposition and reducing insulin resistance, which is not a common approach in many existing treatments. L-arginine is generally well-tolerated and has been shown to have beneficial effects on reducing white fat and improving health, making it a novel option for metabolic improvement.12345
What is the purpose of this trial?
This study aims to assess the safety of ARGX-109 in healthy adults. Another aim is to measure the amount of ARGX-109 in the blood over time to learn how it moves through the body and acts in the body. Each participant will remain in the study for approximately 20 weeks.
Eligibility Criteria
This trial is for healthy adults who want to help test the safety of a new medication called ARGX-109. Participants will be involved in the study for about 20 weeks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either ARGX-109 or placebo to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ARGX-109
Find a Clinic Near You
Who Is Running the Clinical Trial?
argenx
Lead Sponsor
Tim Van Hauwermeiren
argenx
Chief Executive Officer since 2008
B.Sc. and M.Sc. in Bioengineering from Ghent University, Executive MBA from The Vlerick School of Management
Dr. Peter Ulrichts
argenx
Chief Medical Officer since 2023
MD from Maastricht University, PhD in Molecular Immunology from Maastricht University